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Photodynamic therapy (PDT) is a minimally-invasive surgical tool successfully targeting premalignant and malignant
disorders in the head and neck, gastrointestinal tract, lungs and skin with greatly reduced morbidity and
disfigurement. The technique is simple, can commonly be carried out in outpatient clinics, and is highly acceptable
to patients. The role of photodynamic therapy in the management of oral potentially malignant disorders and early
oral cancer is being discussed.Introduction
Potentially malignant oral disorders
Potentially malignant oral disorders, previously called
potentially malignant lesions or conditions or oral dys-
plasia, are identified by exclusion of other white and red
lesions. Leukoplakias and erythroplakias represent the
majority of these disorders. Other, less commonly ones
include oral lichen planus, oral submucous fibrosis, ac-
tinic cheilitis, xeroderma pigmentosum, Fanconi’s an-
aemia and immunodeficiency (i.e. immunosuppressive
agents, human immunodeficiency virus and chronic graft
versus host disease) [1-3].
The worldwide prevalence of oral leukoplakia is about
2%. Chronic smokers and drinkers are more likely to de-
velop this disorder. There is conflicting evidence linking
human papilloma virus to oral leukoplakia [1-3]. Clinical
features can be homogeneous or non-homogeneous (ery-
throleukoplakia); the latter can be either speckled or
nodular. Verrucous leukoplakia, another variant of non-
homogenous leukoplakia, has higher tendency to malig-
nant transformation. The prevalence of oral erythropla-
kia, in selected studies, is less than 1%. Risk factors are
similar to the ones of oral leukoplakia [1-3].* Correspondence: waseem_wk1@yahoo.co.uk
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the origThe current gold standard for identifying dysplastic
changes in tissue is histopathology, by identifying archi-
tectural changes and cellular atypia. Epithelial precursor
lesions in this area involve squamous hyperplasia, mild,
moderate, or severe dysplasia, and carcinoma in situ.
Several authorities have identified substantial interobser-
ver and intraobserver variation in the assessment of oral
dysplastic lesions and their categorisation [1-3].
The management of these oral potentially malignant
disorders is not well defined. However, centres around
the world seem to agree on the basic principles. These
include reducing risk/exposure factors, complete removal
of the lesion and followed-up by continuous monitoring,
which can be lifelong. The indications for active inter-
vention are therapeutic, due to the presence of symp-
toms, and preventive, to pre-empt potential malignant
transformation. Lesion removal is usually employed via
surgical excision with cold instrumentation, laser sur-
gery, cryosurgery and photodynamic therapy. The use of
retinoids and mouthwash with attenuated adenovirus
seems to have a role in the management [1-3].
Oral cancer
Cancers of the oral cavity are the sixth most common
cancers in the world. Unfortunately the incidence con-
tinues to increase with moderate survival rates, despite
the recent advances in surgery and radiotherapy [4-6].
Oral squamous cell carcinoma (OSCC) continues to
affect more males than females with a ratio of 1.5-1 in
the fifth or sixth decade of their lives. However, there istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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under the age of 45 years, accounting to about 6 % of all
age groups. Higher incidence of oral squamous cell car-
cinoma has been identified in South and Southeast Asia,
Latin America, and the Caribbean, and in some parts of
the western world, especially France. The incidence of
oral cancer has also been found to be higher in ethnic
minorities in other developed countries [4-6].
The most common oral sites to be affected with squa-
mous cell carcinoma include the lateral border of the
tongue, the ventral tongue and floor of mouth. In the
Asian population, the buccal mucosa is commonly
affected due to betel quit/tobacco chewing habits [4-6].
The tumour size is one of the most important factors
affecting prognosis. This usually affects the clinician's
ability to decide between ablative surgery, radiotherapy,
chemotherapy, photodynamic therapy or just proceed to
palliative care which could include a combination of any
of the above therapies. Also, it is well documented that
increased tumour size is related to local and regional dis-
ease spread, higher recurrence rates and poor prognosis
[7-11].
Loco-regional spread to the cervical chain complicates
treatment options and worsen the outcome. Several fac-
tors have been known to influence local and regional
tumour spread to the lymphatics. These include the pri-
mary site, tumour volume, double DNA aneuploidy,
poorly differentiated tumours, infiltrating-type invasive
front and perineural and peri/endovascular invasion. Dis-
tant tumour spread occurs most commonly in uncon-
trolled local and regional disease and N-stage disease
[7-11].
The influence of the histological grading as a prognostic
factor in oral squamous cell carcinoma have been docu-
mented in several studies and found to be a significant
predictor of local and regional failure as well as tumour re-
currence. Positive close tumour margins are usually asso-
ciated with high risk of local recurrence and have a
negative effect on survival [7-11].
Photodynamic therapy
Photodynamic therapy (PDT) is a minimally invasive mo-
dality, successfully targeting premalignant and malignant
disorders in the head and neck, gastrointestinal tract, lungs
and skin. Unlike other treatment options, it is associated
with greatly reduced morbidity and disfigurement. The
technique is simple and can usually be carried out in out-
patient clinics, with a high patient-tolerance rate. PDT is
based on initial sensitization of the target tissue with an
agent with photosensitizing properties. The agent select-
ively accumulates in target tissue. The subsequent light de-
livery to the target tissue results in cellular destruction.
The photochemical reaction following PDT is non-
thermal (cold). The photosensitising agents exhibit aninherently low systematic toxicity and, significantly, have a
remarkably little effect on connective tissues, thus result-
ing in healing with minimal scarring. When used in hollow
organs such as the airways, the luminal integrity is retained
without fibrous tissue formation. Major blood vessels
maintain their mechanical integrity as collagen and elastin
are largely spared. This therapy can be applied in conjunc-
tion with any of the conventional treatment modalities (i.e.
surgery, radiotherapy or chemotherapy). The treatment
can be repeated as often as necessary since it has no cu-
mulative toxicity [12-14].
At the time of writing, three first-generation photosensi-
tisers have been approval by regulatory authorities. These
are: Photofrin (porfimer sodium), 5-ALA (5-aminolaevula-
nic acid) and Verteporfin (BPD, benzoporphyrin deriva-
tive). Photofrin was the first photosensitiser to have
received approval, and it is now licensed for the use in the
oesophagus, lung, stomach, cervix and bladder. 5-ALA is a
naturally occurring precursor in the heme biosynthetic
pathway, and, to date, it has received approval only for
non-malignant and pre-malignant disorders. It is con-
verted to the endogenous photosensitiser protoporphyrin
IX, which then can be activated by red, green and even
blue light.
Development and introduction of newer photosensitisers
and light delivery systems have substantially reduced treat-
ment times and residual photosensitivity, while increasing
the range of effective depth (i.e. necrosis and peri-lesional
inflammation), [12-14]. A potent second-generation photo-
sensitiser, Foscan (temoporfin; meta-tetrahydroxyphenyl
chlorine) has been approved for treatment of advanced
head and neck cancer. It is activated at 652 nm, with a re-
sidual photosensitivity of 2–6 weeks [12-14].
Most photosensitisers are administered systemically,
although some can be applied topically (i.e. for skin path-
ology applications). The depth of effect that can be
achieved depends on the photosensitiser used. These are
drugs that are incorporated directly into cellular mem-
branes, but they do not seem to accumulate within cell
nuclei. The direct cytotoxic activity and microvascular
damage contribute to the destruction of tumour cells,
which is manifested as inflammatory swelling and forma-
tion of necrotic tissue. This tissue eventually sloughs
away (or is resorbed), followed by normal healing and re-
epitheliasation [12-14]. Systemic administration of the
photosensitiser leads to a period of unwanted residual
photosensitivity that must be managed until the drug is
eliminated [12-14].
Treatment times vary substantially. The time is related
to the absorption of light by the photosensitiser and also
the efficiency of transfer of light energy to oxygen. Light-
emitting diodes and xenon lamp sources are commonly
used for dermatological application, but lasers are the
most convenient and controllable light source [12-14].
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The management of patients with premaligant lesions of
the oral mucosa in “field cancerization”, with multi-
centric foci of invasion, presents a considerable problem
for the surgeon. Radiotherapy is not always feasible since
it can only be given once and is associated with signifi-
cant local morbidity. Grant et al. [15] reported the use of
PDT to treat 11 patients with “field cancerization” occur-
ring in the oral cavity. Six patients had multiple primary
cancers and five had single primary tumours. Six to eight
weeks later, treated areas in 10 of the 11 patients showed
a complete response to PDT. One patient had areas of
residual leukoplakia; while 2 patients developed further
areas of leukoplakia or erythroplakia within 12 months.
However, no patient has had evidence of recurrent inva-
sive carcinoma in the treated areas.
In another study [16], 18 patients were treated with ALA-
PDT for histologically proven premalignant and malignant
lesions of the mouth. There was a consistent epithelial ne-
crosis with excellent healing in all cases. This study found
that ALA-PDT is a simple and effective way to manage
these patients. More recently, Tsai et al. [17] developed a
light-emitting diode (LED) array combined with topical 5-
aminolevulinic acid (ALA) for photodynamic therapy
(PDT) and evaluated its effectiveness for the treatment of
potentially malignant oral disorders. The clinical part of the
study included a total of 33 oral lesions which included leu-
koplakia, verrucous hyperplasia, erythroleukoplakia, and
verrucous carcinoma. Using the LED light source, a total of
24 leukoplakia lesions were treated with ALA-PDT. The re-
sult was, a complete response in three, a partial response in
nine, and no response in twelve lesions. In the five lesions
of verrucous hyperplasia, complete responses were found in
four while partial response, in the remaining one patient.
Partial responses were found in the two erythroleukoplakia
and one verrucous carcinoma lesions. They concluded that
ALA-PDT is effective for premalignant disorders. We agree
with the statement but believe that higher response rates
can be achieved.
An interesting study by Rigual et al. [18], assessing the
response of dysplasia, carcinoma in situ, and T1 carcinoma
of the oral cavity and larynx to photodynamic therapy with
porfimer sodium. Responses were evaluated at 1 week and
at 1 month and then at 3-month intervals thereafter.
Twenty-four patients had a complete response, 1 had a
partial response, and 1 had no response. Three patients
with oral dysplasia with an initial complete response
experienced recurrence in the treatment field. All the
patients with no response, a partial response, or recurrence
after an initial complete response underwent salvage treat-
ment. Temporary morbidities included oedema, pain,
hoarseness, and skin phototoxicity. They concluded that
porfimer sodium-PDT is an effective treatment option,
with no permanent sequelae.Biel [19] reported his series of 276 patients with early
carcinomas of the oral cavity and larynx. His cure rates
with a single treatment for early laryngeal and oral cancers
were 91% and 94%, respectively. He postulated that PDT is
an effective primary and alternative treatment modality for
early oral cavity and laryngeal cancers. An earlier study by
Hopper et al. [20] on 121 early oral squamous cell carcin-
oma patients treated by mTHPC-PDT showed a complete
response in 85% of protocol-compliant patients (97 of 114
patients). A complete response was maintained in 85% of
responders at 1 year and in 77% at 2 years. One- and 2-
year actuarial survival rates were 89% and 75%, respect-
ively. In the opinion of the investigators, tumour clearance
was accompanied by excellent cosmetic and functional
results, without impact on the patients' performance
status.
Recent studies in our unit
In a prospective study [21] carried out at the UCLH
Head and Neck Centre, a total of 147 consecutive
patients with potentially malignant oral disorders were
treated with surface illumination PDT, using 5-ALA or
mTHPC as the photosensitiser (Figure 1). The average
age was 53 ± 8.9 years. The patients’ recovery was un-
eventful and no complications were noted. Study para-
meters consisted of clinical and histopathological
features, rate of recurrence and malignant transform-
ation. The patients were followed-up for a mean of
7.3 years.
Ex- and current lifelong smokers formed 84.4% of the
recruited patients, while people who currently smoked
and drank, formed 38.1% (56 patients) of the cohort.
Homogenous leukoplakias were identified in 55 patients,
non-homogenous leukoplakias in 73 patients, whereas 19
patients had erythroplakias. Erythroplakias were mainly
identified in heavy lifelong smokers. The most frequent
sites for the lesion were lateral border of tongue, floor of
mouth and retromolar area. Moderate dysplasia was
identified in 33 patients while 63 patients had severe dys-
plasias; 32 patients had a histopathological diagnosis of
carcinoma in situ.
The rate of recurrence following PDT was approxi-
mately 11.6%. Malignant transformation was observed in
11 patients (7.5%), in the tongue, floor of mouth and ret-
romolar area. Recurrence and malignant transformation
was mainly identified in erythroplakias and non-
homogenous leukoplakias. The final outcome of the co-
hort showed that 11 (7.5%) suffered from progressive
disease, 5 (3.4%) had stable disease, 12 (8.2%) were con-
sidered partially responsive to the therapy. Complete re-
sponse was identified in 119/147 patients (81%). These
results provided conclusive evidence that 5-ALA-PDT
and mTHPC-PDT offer an effective alternative treatment
for potentially malignant oral disorders.
Figure 2 Clinical image of SCC of the oral cavity and ventral
tongue responded favourably to photodynamic therapy.
Adapted with permission from: Jerjes W, Upile T, Hamdoon Z, Alexander
Mosse C, Morcos M, Hopper C. Photodynamic therapy outcome for T1/
T2 N0 oral squamous cell carcinoma. Lasers Surg Med. 2011 Aug;43
(6):463–9.
Figure 1 Clinical images showing response of moderate oral
dysplasia to photodynamic therapy. Adapted with permission from:
Jerjes W, Upile T, Hamdoon Z, Mosse CA, Akram S, Hopper.
Photodynamic therapy outcome for oral dysplasia. Lasers Surg Med.
2011 Mar;43(3):192–9.
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centre, a cohort of 38 patients suffering from T1/T2 N0
oral cancer were subjected to mTHPC-photodynamic
therapy and followed up for a minimum of 5 years
(Figure 2). Clinicopathological parameters, recurrence, sur-
vival and disease progression were assessed.
The mean age at the 1st diagnosis of OSCC was
58.0 years. Common clinical presentation was an ulcer in
the tongue, floor of mouth or buccal mucosa. Current/
ex-smokers represented 89.5% of the cohort; while
current/ex-drinkers were 86.8%. Clinically 29 patients
had T1 disease while 9 had T2 disease. Histopathological
diagnosis showed 12 patients with well differentiated
SCC, 16 moderately-differentiated and 10 with poorly-
differentiated cancer. All patients underwent mTHPC-
PDT and were followed-up postoperatively.
A 5-year post-PDT review, 26/38 patients showed
completely normal clinical appearance at the primary
tumour site. Nine patients showed complete response
after one round of PDT treatment, 22 patients under-
went two rounds and 7 patients had three rounds. Re-
cent biopsies from the study cohort showed that 15 hadnormal mucosa, 5 had hyperkeratinisation, 10 had dys-
plastic changes, 2 had carcinoma in situ and 6 showed
recurrent SCC. Overall recurrence was 15.8% and the 5-
year survival was 84.2%. Death from loco-regional and
distant disease spread occurred in 3 patients. The recur-
rence group comprised 6 patients. The mean age of 1st
diagnosis of the recurrence group was 59.3 years.
Most common presentation was an ulcer involving the
buccal mucosa or retromolar area, identified in current/
ex-smokers and current/ex-drinkers. The surgical mar-
gins in this group were also evaluated following laser or
surgical excision, neck dissection and reconstruction.
Based on our experience, we conclude that mTHPC-
photodynamic therapy offers a modality comparable to
other traditional interventions in the management of
low-risk tumours of the oral cavity, with a considerably
less morbidity.
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Photodynamic therapy can be delivered under local or
general anaesthesia and the delivery method can include
surface illumination or interstitial application. The se-
lective uptake and retention of a local or systemically
administered photosensitiser in pathological tissue is an
important factor in PDT. When tumour:normal tissue
photo-differentiation has reached an optimum, the
photosensitiser is activated by non-thermal light of the
appropriate wavelength. This results either in the pro-
duction of oxygen free radicals (type I mechanism) or
the formation of intracellular singlet oxygen (type II
mechanism), which causes tumour cell death by intracel-
lular oxygenation and vascular shutdown mechanisms
[12-14] Although both mechanisms can be activated at
the same time.
The notable adverse events in the immediate post treat-
ment phase include pain and swelling. Pain was experi-
enced at some stage following PDT by all of the patients.
In most cases, pain commenced 24–48 hours following
completion of treatment and lasted for several days [23].
In some instances oral opiate analgesia was necessary. The
use of a local analgesic and anti-inflammatory spray prior
to meals was found to be useful.
Pain was present in 82% of PDT-treated patients while
swelling was limited to only 10%. Pain was generally mild
to moderate in severity and commonly persisted for 2–
4 weeks, decreasing in intensity as the healing pro-
gressed. The pain usually required short-term treatment
with non-steroidal anti-inflammatory drugs (NSAIDs), in
addition to opiates. The reporting of pain was mirrored
by a temporary rise in white blood cell levels, which fol-
lowed the induction of tissue necrosis and the onset of
acute and chronic inflammatory responses [20].
The major side effect of PDT is residual systemic
photosensitization, which lasts for several days or weeks
depending on the type of photosensitiser used. This is
caused by minor concentrations of the photosensitiser in
the skin and may lead to oedema, sunburn, or even
superficial skin necrosis when the skin is exposed to
bright light.
Limitations
So far 5-aminolevulinic acid (5-ALA) is the only photo-
sensitiser that can be applied topically; all others have to
be given intravenously. The advantage of topically ap-
plied ALA is the complete lack of systemic photosensi-
tivity and therefore, ALA-treated patients do not have to
avoid exposure to light following treatment. The major
disadvantage of a topically applied photosensitiser is the
shallow treatment depth of only 1–2 mm that can be
obtained. Therefore only very superficial lesions of less
than 1 mm can be treated successfully with topical appli-
cation [12-14,23].There is little current published data assessing the use
of PDT in the treatment of early tumours (TNM stage
T1/T2 N0) of the head & neck. The advantages of the
use of PDT compared to radiotherapy include its poten-
tial for multiple administration, the ability to treat a
higher resolution tumour volume when combined with
ultrasound guidance for interstitial administration. Its
particularly useful for application in cases of ‘field effect’
of mucosal cancerisation, without jeopardising the po-
tential to use other therapeutic modalities (further sur-
gery, interstitial PDT or radiotherapy) [12-14,23].
The disadvantages to the technology is that it involves
some specialised equipment and training. There is a
large capital outlay however, this is easily negated by the
potential benefits to the patient (quicker administration,
better cosmesis and quality of life) when compared to
some more conventional treatment schedules [12-14,23].
Difficulties arise when the tumour starts to metastasise
through the lymphatic chain. In such cases it is not feas-
ible to induce a therapeutic photochemical reaction in a
whole area of the body (i.e. neck, groin, axilla). A photo-
chemical reaction can be induced in single or multiple
lymph nodes under image-guidance but this can be
sometimes difficult to perform when dealing with a com-
plex lymphatic map as in the neck. Alternative therapies
(i.e. ablative surgery, radiotherapy, chemotherapy) at this
stage can lead to severe problems which can affect form
and function [12-14,20,23].
So far, photodynamic therapy (also known as the fourth
modality, the first three being surgery, radiotherapy and
chemotherapy) has been successfully used in the man-
agement of a variety of pathologies from different ana-
tomical sites. These include the head and neck, brain,
lungs, hepatobiliary tree and other gastrointestinal and
urological pathologies, skin, gynaecological conditions
and in vascular anomalies [24-39].
Conclusions
Photodynamic therapy is an appropriate stand alone
intervention, or as an adjunct to surgery. It is minimally
invasive and can be applied repeatedly at the same site
with no cumulative toxicity. It is also a viable option
where radiotherapy is contraindicated. This modality
causes tissue destruction via the interaction between
oxygen (in tumour tissue), light (of a specific wavelength)
and a photosensitizing drug. The photosensitiser is admi-
nistered intravenously or topically. It is selectively
retained in the target tissues. The nature of the tissue
dictates the interval for maximum accumulation. Laser
light can then be directed at the tumour following a suf-
ficient drug-light interval, thus activating the drug and
initiating the cold (non-thermal) photochemical reaction.
In summary, premalignant and malignant changes in
the mouth, often widespread, are frequently excised or
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option, on its own or in combination with other modal-
ities. Interaction of light with previously administered
photosensitizing agent leads to a local tissue necrosis of
target tissue. There is no cumulative toxicity and the
healing is with remarkably little scarring.
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